

8. Literaturverzeichnis

Eigene Arbeiten:

[A]Schroeder,U.; Bernt,K.M.; Lange,B.; Wenkel,J.; Jikai,J.; Shabat,D.; Amir,R.; Huebener,N.; Niethammer,A.G.; Hagemeyer,C.; Wiebusch,L.; Gaedicke,G.; Wrasidlo,W.; Reisfeld,R.A.; Lode,H.N.(2003): Hydrolytically activated etoposide prodrugs inhibit MDR-1 function and eradicate established MDR-1 multidrug-resistant T-cell leukemia, *Blood* 102 [1], Seite 246-253.

[B] Lange,B.; Schroeder,U.; Huebener,N.; Jikai,J.; Wenkel,J.; Strandsby,A.; Wrasidlo,W.; Gaedicke,G.; Lode,H.N. (2003): Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma, *Cancer Lett.* 197 [1-2], Seite 225-30.

[C]Jikai,J.; Shamis,M.; Huebener,N.; Schroeder,U.; Wrasidlo,W.; Wenkel,J.; Lange,B.; Gaedicke,G.; Shabat,D.; Lode,H.N.(2003): Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase, *Cancer Lett.* 197 [1-2], Seite 219-224.

Arbeiten anderer Autoren:

- [1] Gottesman, M. M.; Fojo, T. und Bates, S. E. (2002): Multidrug resistance in cancer: role of ATP-dependent transporters, *Nat.Rev.Cancer* 2 [1], Seite 48-58. URL: PM:11902585
- [2] Kaufmann, S. H. (1998): Cell death induced by topoisomerase-targeted drugs: more questions than answers, *Biochim.Biophys.Acta* 1400 [1-3], Seite 195-211. URL: PM:9748575
- [3] Hande, K. R. (1998): Etoposide: four decades of development of a topoisomerase II inhibitor, *Eur.J.Cancer* 34 [10], Seite 1514-1521. URL: PM:9893622
- [4] Wang, J. C. (1996): DNA topoisomerases, *Annu.Rev.Biochem.* 65, Seite 635-692. URL: PM:8811192
- [5] Berger, J. M.; Gamblin, S. J.; Harrison, S. C. und Wang, J. C. (1996): Structure and mechanism of DNA topoisomerase II, *Nature* 379 [6562], Seite 225-232. URL: PM:8538787
- [6] Osheroff, N. (1998): DNA topoisomerases, *Biochim.Biophys.Acta* 1400 [1-3], Seite 1-2. URL: PM:9867354
- [7] Wang, J. C. (1985): DNA topoisomerases, *Annu.Rev.Biochem.* 54, Seite 665-697. URL: PM:2992360
- [8] Watt, P. M. und Hickson, I. D. (1994): Structure and function of type II DNA topoisomerases, *Biochem.J.* 303 (Pt 3), Seite 681-695. URL: PM:7980433
- [9] Burden, D. A.; Kingma, P. S.; Froelich-Ammon, S. J.; Bjornsti, M. A.; Patchan, M. W.; Thompson, R. B. und Osheroff, N. (1996): Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes, *J.Biol.Chem.* 271 [46], Seite 29238-29244. URL: PM:8910583
- [10] Zhang, H.; D'Arpa, P. und Liu, L. F. (1990): A model for tumor cell killing by topoisomerase poisons, *Cancer Cells* 2 [1], Seite 23-27. URL: PM:2167111
- [11] Krishan, A.; Paika, K. und Frei E III (1975): Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts, *J.Cell Biol.* 66 [3], Seite 521-530. URL: PM:1057547
- [12] Sullivan, D. M.; Latham, M. D. und Ross, W. E. (1987): Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells, *Cancer Res.* 47 [15], Seite 3973-3979. URL: PM:3038304

- [13] Sullivan, D. M.; Chow, K. C.; Glisson, B. S. und Ross, W. E. (1987): Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents, *NCI.Monogr* [4], Seite 73-78. URL: PM:2819735
- [14] Felix, C. A. (1998): Secondary leukemias induced by topoisomerase-targeted drugs, *Biochim.Biophys.Acta* 1400 [1-3], Seite 233-255. URL: PM:9748598
- [15] Pui, C. H.; Behm, F. G.; Raimondi, S. C.; Dodge, R. K.; George, S. L.; Rivera, G. K.; Mirro, J., Jr.; Kalwinsky, D. K.; Dahl, G. V. und Murphy, S. B. (1989): Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia, *N.Engl.J.Med.* 321 [3], Seite 136-142. URL: PM:2787477
- [16] Kessel, D.; Botterill, V. und Wodinsky, I. (1968): Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response, *Cancer Res.* 28 [5], Seite 938-941. URL: PM:5652307
- [17] Dano, K. (1973): Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells, *Biochim.Biophys.Acta* 323 [3], Seite 466-483. URL: PM:4796512
- [18] Ling, V. und Thompson, L. H. (1974): Reduced permeability in CHO cells as a mechanism of resistance to colchicine, *J.Cell Physiol* 83 [1], Seite 103-116. URL: PM:4855907
- [19] Borst, P. und Elferink, R. O. (2002): Mammalian ABC transporters in health and disease, *Annu.Rev.Biochem.* 71, Seite 537-592. URL: PM:12045106
- [20] Higgins, C. F. (1992): ABC transporters: from microorganisms to man, *Annu.Rev.Cell Biol.* 8, Seite 67-113. URL: PM:1282354
- [21] Gottesman, M. M. und Ambudkar, S. V. (2001): Overview: ABC transporters and human disease, *J.Bioenerg.Biomembr.* 33 [6], Seite 453-458. URL: PM:11804186
- [22] Kong, L. B.; Siva, A. C.; Rome, L. H. und Stewart, P. L. (1999): Structure of the vault, a ubiquitous cellular component, *Structure.Fold.Des* 7 [4], Seite 371-379. URL: PM:10196123
- [23] Scheffer, G. L.; Schroeijers, A. B.; Izquierdo, M. A.; Wiemer, E. A. und Scheper, R. J. (2000): Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer, *Curr.Opin.Oncol.* 12 [6], Seite 550-556. URL: PM:11085454
- [24] Juliano, R. L. und Ling, V. (1976): A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, *Biochim.Biophys.Acta* 455 [1], Seite 152-162. URL: PM:990323
- [25] Gros, P.; Ben Neriah, Y. B.; Croop, J. M. und Housman, D. E. (1986): Isolation and expression of a complementary DNA that confers multidrug resistance, *Nature* 323 [6090], Seite 728-731. URL: PM:3022150
- [26] Ueda, K.; Cornwell, M. M.; Gottesman, M. M.; Pastan, I.; Roninson, I. B.; Ling, V. und Riordan, J. R. (1986): The *mdr1* gene, responsible for multidrug-resistance, codes for P-glycoprotein, *Biochem.Biophys.Res.Commun.* 141 [3], Seite 956-962. URL: PM:2880583
- [27] ALBERT, A. (1958): Chemical aspects of selective toxicity, *Nature* 182 [4633], Seite 421-422. URL: PM:13577867
- [28] Senter, P. D.; Saulnier, M. G.; Schreiber, G. J.; Hirschberg, D. L.; Brown, J. P.; Hellstrom, I. und Hellstrom, K. E. (1988): Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate, *Proc.Natl.Acad.Sci.U.S.A* 85 [13], Seite 4842-4846. URL: PM:3387440
- [29] Zhang, Y. L.; Guo, X.; Cheng, Y. C. und Lee, K. H. (1994): Antitumor agents. 148. Synthesis and biological evaluation of novel 4 beta-amino derivatives of etoposide with better pharmacological profiles, *J.Med.Chem.* 37 [4], Seite 446-452. URL: PM:8120864
- [30] Wrasidlo, W.; Schroder, U.; Bernt, K.; Hubener, N.; Shabat, D.; Gaedicke, G. und Lode, H. (2002): Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs, *Bioorg.Med.Chem.Lett.* 12 [4], Seite 557-560. URL: PM:11844671

- [31] Lode, H. N.; Xiang, R.; Varki, N. M.; Dolman, C. S.; Gillies, S. D. und Reisfeld, R. A. (1997): Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow, *J.Natl.Cancer Inst.* 89 [21], Seite 1586-1594. URL: PM:9362156
- [32] Scudiero, D. A.; Shoemaker, R. H.; Paull, K. D.; Monks, A.; Tierney, S.; Nofziger, T. H.; Currens, M. J.; Seniff, D. und Boyd, M. R. (1988): Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines, *Cancer Res.* 48 [17], Seite 4827-4833. URL: PM:3409223
- [33] O'Brien, I. E.; Reutelingsperger, C. P. und Holdaway, K. M. (1997): Annexin-V and TUNEL use in monitoring the progression of apoptosis in plants, *Cytometry* 29 [1], Seite 28-33. URL: PM:9298808
- [34] Krishan, A. (1990): Rapid DNA content analysis by the propidium iodide-hypotonic citrate method, *Methods Cell Biol.* 33, Seite 121-125. URL: PM:1707480
- [35] Pollack, A. und Ciancio, G. (1990): Cell cycle phase-specific analysis of cell viability using Hoechst 33342 and propidium iodide after ethanol preservation, *Methods Cell Biol.* 33, Seite 19-24. URL: PM:2084468
- [36] Legrand, O.; Perrot, J. Y.; Simonin, G.; Baudard, M. und Marie, J. P. (2001): JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia, *Blood* 97 [2], Seite 502-508. URL: PM:11154229
- [37] Jansen, W. J.; Hulscher, T. M.; Ark-Otte, J.; Giaccone, G.; Pinedo, H. M. und Boven, E. (1998): CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein, *Br.J.Cancer* 77 [3], Seite 359-365. URL: PM:9472629
- [38] Loike, J. D. und Horwitz, S. B. (1976): Effects of podophyllotoxin and VP-16-213 on microtubule assembly *in vitro* and nucleoside transport in HeLa cells, *Biochemistry* 15 [25], Seite 5435-5443. URL: PM:999818
- [39] Sinha, B. K.; Politi, P. M.; Eliot, H. M.; Kerrigan, D. und Pommier, Y. (1990): Structure-activity relations, cytotoxicity and topoisomerase II dependent cleavage induced by pendulum ring analogues of etoposide, *Eur.J.Cancer* 26 [5], Seite 590-593. URL: PM:2169277
- [40] Shabat, D.; Lode, H. N.; Pertl, U.; Reisfeld, R. A.; Rader, C.; Lerner, R. A. und Barbas, C. F., III (2001): *In vivo* activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy, *Proc.Natl.Acad.Sci.U.S.A* 98 [13], Seite 7528-7533. URL: PM:11404472
- [41] Niethammer, A.; Gaedicke, G.; Lode, H. N. und Wrasidlo, W. (2001): Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility, *Bioconjug.Chem.* 12 [3], Seite 414-420. URL: PM:11353540
- [42] Wrasidlo, Wolfgang; Niethammer, Andreas; Deger, Serdar; Sehouli, Jolid; Kulozik, Andreas; Geilen, Wilhelm; Henze, Gunter; Gaedicke, Gerhard und Lode, Holger N. (2002): Pilot study of hydrolytically activated paclitaxel prodrug therapy in patients with progressive malignancies, *Current Therapeutic Research* 63 [4], Seite 247-262. URL: <http://www.sciencedirect.com/science/article/B6VS8-467SPMX-2/2/138e0c0b80cc92e6d3af85a4cd750f70>
- [43] Boyer, M. J.; Barnard, M.; Hedley, D. W. und Tannock, I. F. (1993): Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours, *Br.J.Cancer* 68 [5], Seite 890-897. URL: PM:8217605
- [44] Rooseboom, M.; Commandeur, J. N. und Vermeulen, N. P. (2004): Enzyme-catalyzed activation of anticancer prodrugs, *Pharmacol.Rev.* 56 [1], Seite 53-102. URL: PM:15001663
- [45] Tsuruo, T.; Matsuzaki, T.; Matsushita, M.; Saito, H. und Yokokura, T. (1988): Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors *in vitro* and *in vivo*, *Cancer Chemother.Pharmacol.* 21 [1], Seite 71-74. URL: PM:3342468
- [46] Shimada, Y.; Yoshino, M.; Wakui, A.; Nakao, I.; Futatsuki, K.; Sakata, Y.; Kambe, M.; Taguchi, T. und Ogawa, N. (1993): Phase II study of CPT-11, a new camptothecin derivative,

- in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group, *J.Clin.Oncol.* 11 [5], Seite 909-913. URL: PM:8487053
- [47] Silva, K. L.; Vasconcelos, F. C.; Marques-Santos, L. F.; Kwee, J. K. und Maia, R. C. (2003): CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype, *Leuk.Res.* 27 [3], Seite 243-251. URL: PM:12537977
- [48] Thomas, H. und Coley, H. M. (2003): Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein, *Cancer Control* 10 [2], Seite 159-165. URL: PM:12712010
- [49] Aligiannis, N.; Pouli, N.; Marakos, P.; Mitaku, S.; Skaltsounis, A. L.; Leonce, S.; Pierre, A. und Atassi, G. (2000): Design, synthesis and biological activity of 7-O-(4-O-acetyl-3-iodo-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl) daunomycinone and 7-O-(3-chloro-2,3,6-trideoxy-4-O-propanoyl-alpha-L-lyxo-hexopyranosyl)daunomycinone, *Chem.Pharm.Bull.(Tokyo)* 48 [1], Seite 150-153. URL: PM:10705494
- [50] Tishler, R. B.; Schiff, P. B.; Geard, C. R. und Hall, E. J. (1992): Taxol: a novel radiation sensitizer, *Int.J.Radiat.Oncol.Biol.Phys.* 22 [3], Seite 613-617. URL: PM:1346533